READ MORE
Cystic fibrosis news shared on CFRI’s social media pages related to CF research, education, advocacy, patient wellness support and more!
AUGUST, 2022
CHIESI USA ANNOUNCES THE REIMAGINED CHIESI CAREDIRECT WELLNESS PROGRAM
PFIZER, BIONTECH ASK FDA TO AUTHORIZE UPDATED BIVALENT COVID-19 VACCINE BOOSTER
POSITIVE COVID DIAGNOSIS TIED TO HIGHER HEALTHCARE UTILIZATION SIX MONTHS AFTER ILLNESS
BLOCKING PD-1 PROTEIN ACTIVATION MAY RESULT IN BETTER BACTERIA ELIMINATION
KALYDECO AT LOWER DOSAGE MAY BE AS EFFECTIVE AS HIGHER DOSE
STUDY IDENTIFIES THERAPEUTIC TARGETS FOR SEVERE COVID IN CF PATIENTS
UK APPROVES MODERNA’S BIVALENT COVID-19 VACCINE BOOSTER
NOVAVAX FILES FOR U.S. AUTHORIZATION FOR USE OF COVID-19 VACCINE AS BOOSTER
LGG SUPPLEMENT MAY EASE CF SYMPTOMS BY CHANGING GUT MICROBIOME
PHASE 1 TRIAL OF XENLETA, ANTIBIOTIC FOR MRSA INFECTIONS, FULLY ENROLLED
EVIDENCE TO SUPPORT EARLY CFTR MODULATOR TREATMENT FOR CHILDREN WITH CF KEEPS GROWING
CONCERN GROWS THAT TRANSPLANT RECIPIENTS UNABLE TO ACCESS EVUSHELD – FIND EVUSHELD NEAR YOU
MOST ADULTS IN CF STUDY HAVE LOW BONE MINERAL DENSIT
BIOTECH COMPANY F2G DEVELOPING NEW CLASS OF ANTIFUNGAL TREATMENT
GLUCERNA, OATLY DRINKS AMONG 53 BEVERAGES RECALLED FOR POTENTIAL MICROBIAL CONTAMINATION
YARR LEADERSHIP ACADEMY APPLICATIONS ARE NOW OPEN
US CITIES, COUNTIES WEIGH REINSTATING MASK MANDATES AS COVID-19 CASES AND HOSPITALIZATIONS RISE
STUDY EXAMINES PREVALENCE OF LONG COVID IN CHILDREN
FEDERAL COURT IN TEXAS TO HEAR NEW CHALLENGE TO ACA
GLP-1 HORMONE INFUSIONS MAY BOOST INSULIN PRODUCTION IN CF PATIENTS
WNK INHIBITION INCREASES SURFACE LIQUID PH AND HOST DEFENSE IN CF AIRWAY EPITHELIA
LUNG ALLOCATION SCORE AND OTHER PREDICTION MODELS LACK ACCURACY FOR POST-LUNG TRANSPLANT SURVIVAL
INHALED ANTIBIOTICS TIED TO GREATER RISK OF ASPERGILLUS INFECTION
JULY, 2022
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) LAUNCHING PHAGE THERAPY CLINICAL TRIAL
TRAVEL BENEFIT: FREE FLIGHTS FOR PATIENTS AND FAMILIES IN NEED
YARR LEADERSHIP ACADEMY APPLICATIONS ARE NOW OPEN
BA.5 OMICRON SUBVARIANT FOUR TIMES MORE RESISTANT TO COVID-19 VACCINES
PANDEMIC LED TO SURGE IN SUPERBUG INFECTIONS AND RELATED DEATHS IN US HOSPITALS
COLORADO CF COMMUNITY MEMBERS: RDAC IS BEING CREATED
GUT BACTERIA FROM ACID REFLUX MAY PROMOTE CF LUNG INFLAMMATION
MACROCYCLE MAY HELP IMPROVE CFTR FUNCTION
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) LAUNCHING PHAGE THERAPY CLINICAL TRIAL
MODERNA DEVELOPING TWO POTENTIAL OMICRON-TARGETING COVID-19 VACCINE BOOSTER SHOTS
SABIZABULIN CUT RISK OF DEATH FOR PEOPLE HOSPITALIZED WITH COVID-19 BY HALF
PATIENTS OF COLOR RECEIVE LESS SUPPLEMENTAL OXYGEN IN ICU THAN WHITE PATIENTS
MEASURING TISSUE STIFFNESS MAY HELP WITH DIAGNOSIS OF CF LIVER DISEASE
NOVEL METHOD DEVELOPED TO REDUCE RISK OF BACTERIAL INFECTION IN CYSTIC FIBROSIS
MS THERAPY BOOSTS TOBRAMYCIN’S EFFECTIVENESS AGAINST P. AERUGINOSA
‘VIRAL RESERVOIR’ OF SPIKE PROTEIN MAY EXPLAIN LONG-TERM COVID-19 SYMPTOMS
OMICRON-TARGETING COVID-19 VACCINE BOOSTERS TO ROLL OUT IN THE FALL
MORE FREQUENT LUNG TESTS FOUND TO IMPROVE LUNG FUNCTION IN CF YOUTH
UNC STUDY RESULT: TRIKAFTA AFTER CF LUNG TRANSPLANT NOT WELL-TOLERATED
SIGNS OF EARLY-ONSET LUNG DISEASE SEEN IN HALF OF MONITORED CF INFANTS
USE OF CFTR MODULATORS MAY PROTECT AGAINST SEVERE COVID-19
AN EXTENDED FAMILIA FOR LATINOS LIVING WITH CF
PAUSE IN IMMUNE SUPPRESSION MEDICATION SHOWN TO IMPROVE ANTIBODY RESPONSE TO COVID VACCINE
FDA ADVISERS RECOMMEND UPDATING COVID BOOSTER SHOTS FOR THE FALL
CURES 2.0 SEEKS TO SPEED DELIVERY OF TREATMENTS FOR RARE DISEASES
SENATORS LEAD BIPARTISAN EFFORT TO CURB INSULIN PRICES
STUDY HIGHLIGHTS PULMONARY EXACERBATION SUBPHENOTYPES IN CYSTIC FIBROSIS PATIENTS
PROBIOTIC VIVOMIXX MAY HELP TO RESTORE GUT MICROBIOME, EASE CFRD
CF CARRIER PREVALENCE MAY FACTOR IN VARIABILITY IN COVID-19 OUTCOMES
DOSING BEGINS IN CLINICAL TRIAL OF NEBULIZED PHAGE THERAPY FOR P. AERUGINOSA INFECTIONS
STEM CELL AGENCY JOINS CONSORTIUM DEVELOPING GENE THERAPIES FOR RARE DISEASES
CARBON BIOSCIENCES TO DEVELOP NEW VIRAL VECTOR FOR CF GENE THERAPY
ANTIBIOTIC CHANGE NOT SEEN TO IMPROVE LUNG FUNCTION AFTER FLARE
EARLY TREATMENT WITH AZITHROMYCIN HAS SOME BENEFITS FOR CF INFANTS
COVID-19 POSES GREATER DANGER TO CHILDREN THAN SEASONAL FLU
JUNE, 2022
VIRUSES RARELY SEEN DURING THE PANDEMIC ARE SPREADING AGAIN
COVID-19 ANTIBODIES MAY PERSIST NEARLY 500 DAYS AFTER INFECTION
FDA ADVISORY COMMITTEE SUPPORTS AUTHORIZATION OF NOVAVAX’S COVID-19 VACCINE
FTC LAUNCHES INQUIRY INTO PRESCRIPTION DRUG MIDDLEMEN INDUSTRY
PP-007 RESOLVES LUNG INFLAMMATION IN CF MOUSE MODEL
FUNDING AWARDED FOR RESEARCH INTO AMINOGLYCOSIDES AND HEARING LOSS
DATA SHOW SEVEN-DAY AVERAGE OF COVID-19 CASES IS SIX TIMES HIGHER THAN LAST YEAR AT THIS TIME
CDC RECOMMENDS RE-ISOLATION IF COVID RECURS AFTER TREATMENT WITH PAXLOVID
ETHNIC MINORITIES LESS LIKELY TO BE ELIGIBLE FOR TRIPLE COMBINATION CFTR MODIFIER
BREATH BIOMARKERS SHOW POTENTIAL FOR IDENTIFYING NTM LUNG INFECTIONS
$2.7M NIH GRANT SUPPORTS WORK INTO STEM CELL ROLE IN LUNG INFLAMMATION
MAY, 2022
BACTERIOPHAGES ELIMINATE TREATMENT-RESISTANT M. ABSCESSUS LUNG INFECTION
NEARLY 60% OF U.S. POPULATION HAS HAD CORONAVIRUS INFECTION
ABBVIE HALTS DEVELOPMENT OF ABBV-119 CORRECTOR, WILL CONTINUE WORKING TOWARDS TRIPLE COMBINATION
LUNG CLEARANCE INDEX ABLE TO IDENTIFY CHILDREN WITH CF AT RISK OF EXACERBATIONS
LUNG-PANCREATIC CELL TRANSPLANT SAFE, EFFECTIVE IN CF PATIENTS WITH CFRD
FEDERAL ADMINISTRATION TO PROMOTE SUPPLY OF AND IMPROVE ACCESS TO PAXLOVID
CDC RECOMMENDS MOST AMERICANS UNDER 50 SHOULD WAIT FOR NEXT GENERATION OF COVID-19 VACCINE BOOSTERS
FDA GRANTS FULL APPROVAL TO REMDESIVIR FOR TREATMENT OF COVID-19 IN CHILDREN
SALIVA OF ADULTS WITH CF CONTAINS ANTI-INFLAMMATORY FATTY MOLECULES
NANOPARTICLES IMPROVE DRUG DELIVERY FOR LUNG DISEASES
COMMON ENVIRONMENTAL FUNGUS CAN WORSEN LUNG FUNCTION IN CHILDREN WITH CF
APRIL, 2022
RISK OF BREAKTHROUGH INFECTIONS TIED TO PSYCHIATRIC PROBLEMS
INHALED HYPERTONIC SALINE TIED TO BENEFICIAL LUNG CHANGES IN YOUNG CHILDREN WITH CF
SIONNA THERAPEUTICS RECEIVES FUNDING FROM ORBIMED AND THE CF FOUNDATION FOR MODULATOR DEVELOPMENT
FIRST PATIENT ENROLLED IN PHASE 1 TRIAL TESTING ANTIBIOTIC XENLETA FOR CF
ATS PAR PATIENTS & EXPERTS FORUM – IMPROVING LUNG HEALTH: WHAT’S ON THE HORIZON
FDA GRANTS EMERGENCY USE AUTHORIZATION TO COVID-19 BREATHALYZER TEST
CDC ASKS JUSTICE DEPARTMENT TO APPEAL TRANSPOPRTATION MASK RULING
NONINVASIVE ELASTOGRAPHY PREDICTS LIVER SCARRING SEVERITY IN CHILDREN
FIRST PATIENT DOSED IN TRIAL OF AEROSOL-DELIVERED GENETIC MEDICINE
COLORADO RARE DISEASE ADVISORY COUNCIL LEGISLATION INTRODUCED
OREGON SEEKS TO LIMIT MEDICAID COVERAGE OF ACCELERATED-APPROVAL DRUGS
CALL FOR CF PATIENT NOMINATIONS: WHAT’S YOUR GAP?
MEDICARE BEGINS COVERING AT-HOME COVID-19 TESTS FOR PART B BENEFICIARIES
OMICRON SUBVARIANT BA.2 ACCOUNTS FOR 72.2% OF COVID-19 VARIANTS IN US, CDC ESTIMATES
CYSTIC FIBROSIS CARRIERS ARE AT INCREASED RISK FOR A WIDE RANGE OF CF-RELATED CONDITIONS
KIT2014 INCREASED CFTR MODULATOR EFFICACY IN PRECLINICAL STUDY
MANY UNINSURED LOSE ACCESS TO FREE COVID-19 TESTING, TREATMENT, AND VACCINES
FDA AUTHORIZES SECOND BOOSTER SHOTS FOR ADULTS AGED 50 AND OLDER
ANTIBIOTICS LESS EFFECTIVE AGAINST MIX OF MICROBES IN LUNG INFECTION
METABOLITES ASSOCIATED WITH LOWER AIRWAY INFECTION AND INFLAMMATION
AB 1880 INTRODUCED TO CA ASSEMBLY COMMITEE ON HEALTH.
MARCH, 2022
TOP-RATED CHARITIES TO HELP THE UKRAINE RELIEF EFFORT
DIABETES SISTERS PROVIDE OVERVIEW OF INSULIN OPTIONS
DRUG COMPANIES REACH DEAL TO PRODUCE LOW-COST VERSIONS OF PFIZER’S COVID-19 DRUG
MODERNA ASKS FDA TO AUTHORIZE SECOND COVID-19 BOOSTER DOSE FOR ALL ADULTS
HIGH LEVELS OF DMBT1 PROTEIN IN LUNGS MAY MARK CF PROGRESSION
BACTERIA BOOSTS ANTI-FUNGAL MEDICINE’S KILLING POWER IN CF STUDY
CANADIAN RESEARCHERS TO STUDY NEW CELL TYPES IN CF
LIPID-DRIVEN CFTR CLUSTERING IS IMPAIRED IN CF AND RESTORED BY TRIKAFTA
HOW TO DEAL WITH AN INSURANCE DENIAL – FACT SHEET AVAILABLE
GUNNAR ESIASON OP-ED SHEDS LIGHT ON DANGERS OF FLAWED HEALTH TECHNOLOGY ASSESSMENTS
REINFECTIONS WITH OMICRON CORONAVIRUS SUBVARIANTS POSSIBLE BUT RARE
FULLY VACCINATED PEOPLE LESS LIKELY TO SUFFER FROM LONG COVID
IVERMECTIN DOES NOT PREVENT PATIENTS WITH COVID-19 FROM BECOMING SEVERELY ILL
CLINICAL EFFECTIVENESS OF ELEXACAFTOR/ TEZACAFTOR/IVACAFTOR IN PEOPLE WITH CF
HOW TO DEAL WITH AN INSURANCE DENIAL – FACT SHEET AVAILABLE
FDA WARNS AGAINST THREE UNAUTHORIZED COVID-19 TESTS OVER CONCERNS OF FALSE RESULTS
COVID-19 PATIENTS IN HIGH-VULNERABILITY ZIP CODES AT GREATER RISK FOR WORSE HEALTH OUTCOMES
HEALTH CANADA CLEARS MEDICAGO’S PLANT-BASED COVID-19 VACCINE FOR USE IN ADULTS
RESULTS FROM SURVEY OF PEOPLE WITH CF INELIGIBLE TO TAKE CFTR MODULATORS
KROGER COMMUNITY REWARDS PROGRAM: SIGN UP TO SUPPORT CFRI
LUNG FUNCTION OF CHILDREN WITH CYSTIC FIBROSIS DIFFERENT IN US VS UK
A SINGLE-CELL ATLAS OF LARGE AND SMALL AIRWAYS AT BIRTH IN A PORCINE MODEL OF CF
TRIKAFTA LEADS TO REDUCED NEED FOR ANTIBIOTICS, FEWER HOSPITALIZATIONS
EUROPEAN CYSTIC FIBROSIS ORGANIZATIONS UNITE TO RAISE FUNDS FOR UKRAINIANS WITH CF
RARE DISEASE ADVISORY COUNCILS EXPLAINED IN TWO MINUTES
CFRI CO-SIGNS LETTER IN SUPPORT OF MD HB 1015
HELP COPAYS ACT SEEKS TO FIGHT HIGH OUT-OF-POCKET INSURANCE COSTS
COVID ANTIBODY DRUG EVUSHELD OFTEN GOES UNUSED
EVEN MILD CASES OF COVID CAN CAUSE BRAIN DAMAGE AND SHRINKAGE
FEBRUARY, 2022
ACHROMOBACTER INFECTION IN CHILDREN LINKED TO WORSE LUNG FUNCTION
PARTIAL MONOCYTE TRANSPLANT IMPROVES SURVIVAL IN MOUSE STUDY
ADMINISTRATION TO PROVIDE AMERICANS WITH 400M FREE N95 MASKS
FDA HALTS USE OF TWO COVID-19 MONOCLONAL ANTIBODY THERAPIES
PFIZER BEGINS TESTING OMICRON-SPECIFIC COVID VACCINE IN ADULTS
CFRI CO-SIGNS LETTER BY ALL COPAYS COUNT COALITION TO HHS REGARDING CO-PAY ACCUMULATORS
BODY MASS INDEX RECOVERY FOLLOWING LUNG TRANSPLANT FOR CYSTIC FIBROSIS
EXON-SKIPPING MOLECULES SHOW POTENTIAL TO TREAT NONSENSE MUTATIONS IN CF
KAFTRIO RESCUES CHLORIDE, BICARBONATE DEFICITS IN GI TISSUES\
FDA GRANTS FULL APPROVAL TO MODERNA’S COVID-19 VACCINE
NEW ONLINE RESOURCE TO TRACK USE OF QALY ACROSS STATES
SELF-SCREENING TOOL DEVELOPED FOR NONWHITE CF POPULATIONS
OVER HALF OF CHILDREN WITH CF SHOW POOR CARDIORESPIRATORY FITNESS IN STUDY
PERSONALIZED MEDICINES FOR RARE MUTATIONS FOCUS OF EU PROJECT
HEALTH INSURERS BEGIN CHARGING PATIENTS FOR COVID-19 CARE
COVID-19 AEROSOL PARTICLES FOUND BOTH INSIDE AND OUTSIDE OF ROOMS OF PEOPLE SELF-ISOLATING AT HOME
POTENTIAL RISK OF STRANGULATION IN CHILDREN WHO USE ENTERAL FEEDING DELIVERY SETS
JANUARY, 2022
MOLECULE SHOWS EARLY POTENTIAL IN TREATING CF DUE TO F508DEL MUTATION
SINUS SURGERY MOST SUCCESSFUL IF PERFORMED WITHIN FIRST YEARS AFTER LUNG TRANSPLANT
TRIKAFTA MAY IMPROVE VITAMIN D ABSORPTION IN CF PATIENTS
FDA WARNS ANTIGEN TESTS MAY BE LESS EFFECTIVE IN DETECTING OMICRON VARIANT
PLATFORMS OF HOPE: ADVANCES IN GENE THERAPY & GENE EDITING
ENBIOTIX RAISES $11M TO DEVELOP ANTIBIOTICS FOR LUNG INFECTIONS
IRON BUILDUP MAY LEAD TO DEATH OF CF AIRWAY CELLS
BIOMX RECEIVES GRANT FOR PHASE 1/2 TRIAL OF PHAGE THERAPY FOR P. AERUGINOSA INFECTIONS
STUDY SHOWS POSITIVE IMPACT OF CFTR MODULATORS ON ABILITY TO FEND OFF SEVERE COVID-19
COVID-19 HOSPITALIZATIONS AMONG CHILDREN AT RECORD NUMBERS AMID OMICRON SURGE
FDA AUTHORIZES COVID-19 VACCINE BOOSTERS FOR CHILDREN 12-15 YEARS
CREATIVE EFFORT TO ENCOURAGE VACCINATIONS: 700 SHEEP AND GOATS ARRANGED IN THE SHAPE OF A SYRINGE
BIOBONDS LEGISLATION FEATURED IN OP-ED
PEPTILOGICS RECEIVES GRANT TO RESEARCH THERAPIES TO FIGHT LUNG BACTERIA
SPL84-23 FOR CF SPLICING MUTATION NAMED ORPHAN DRUG IN U.S. AND EUROPE
GRANT AWARDED TO SUPPORT RESEARCH FOR TREATMENT OF CHRONIC RHINOSINUSITIS
EVERY VACCINATED PARTICIPANT WITH SERIOUS COVID-19 OUTCOMES HAD AT LEAST ONE RISK FACTOR
LATEST DATA ON COVID-19 VACCINATIONS BY RACE AND ETHNICITY
HIGH LEVELS OF T CELLS FROM COMMON COLD MAY HELP PREVENT COVID-19
FEDERAL WEB SITE FOR AMERICANS TO REQUEST FREE COVID-19 TESTS LAUNCHED
NEW CAPSULE FORM OF ADRULIPASE ALFA FOR EPI MAY SOON ENTER TRIAL
FELDAN THERAPEUTICS RECEIVES FUNDING TO DEVELOP TECHNOLOGY TO IMPROVE MEDICINE DELIVERY
TRIKAFTA RESCUES CFTR AND LOWERS MONOCYTE P2X7R-INDUCED INFLAMMASOME ACTIVATION IN CF
CLOTH MASKS NOT AS EFFECTIVE AS SURGICAL MASKS, RESPIRATORS AGAINST COVID-19
DECEMBER, 2021
7 MILLION UNINSURED PEOPLE ARE ELIGIBLE FOR MEDICAID OR CHIP
OVERUSE OF ANTIBIOTICS DURING PANDEMIC FUELING DRUG-RESISTANT INFECTIONS
PFIZER AND BIONTECH SAY THEIR COVID-19 VACCINE IS 100% EFFECTIVE IN ADOLESCENTS AGED 12 TO 15 YEARS
LUNG AIRWAY CHIP ACCURATELY MODELS CYSTIC FIBROSIS
TRIKAFTA INCREASES MICROBIOME DIVERSITY IN LUNGS
CREATION OF BILE DUCT CELLS MAY HELP TREAT CF LIVER DISEASE
FDA PANEL SUPPORTS EMERGENCY USE OF MERCK COVID DRUG
NEW AND POTENTIALLY MORE TRANSMISSIBLE CORONAVIRUS VARIANT CAUSES CONCERN
LUNG TRANSPLANTS FOR COVID-19 PATIENTS ARE RISING QUICKLY
OPINION: HOW HEALTH CARE SYSTEMS DO, AND DO NOT, SUPPORT PATIENTS
NEW ATS DOCUSERIES ON RESPIRATORY HEALTH
FDA AUTHORIZES NEW MONOCLONAL ANTIBODIES FOR PREVENTION OF COVID-19 IN CERTAIN INDIVIDUALS
FDA AUTHORIZES ELI LILLY’S COVID-19 MONOCLONAL ANTIBODY TREATMENT FOR YOUNG, AT-RISK CHILDREN
NASAL EPITHELIAL CELLS GROWN IN CULTURE SHOW POTENTIAL TO BE USED IN CF STUDIES
FULL CFTR GENE ANALYSIS IDENTIFIES MUTATIONS THAT ARE MISSED IN STANDARD TESTING
SELF-COMPASSION TIED TO BETTER QUALITY OF LIFE IN ADULTS WITH CF
PULMOCIDE RECEIVES GRANT TO SUPPORT WORK ON ANTIFUNGAL THERAPY FOR LUNG TRANSPLANTS
BLOCKING PROTEIN OF GLUCOSE UPTAKE, SGLT1, MAY HELP IN TREATING CF
MANY WOMEN WITH CF LACK INFORMATION ON FERTILITY PRESERVATION
OMICRON VARIANT: LESS SEVERE ILLNESS, MORE RESISTANT TO PFIZER-BIONTECH COVID-19 VACCINE
PFIZER SAYS ITS ANTIVIRAL COVID-19 PILL IS NEARLY 90% EFFECTIVE IN FINAL ANALYSIS
1.1M DEATHS, 10.3M HOSPITALIZATIONS PREVENTED DURING FIRST YEAR OF US COVID-19 VACCINE PROGRAM
THE “NO SURPRISES ACT” WILL TAKE EFFECT IN JANUARY 2022
LIFE EXPECTANCY FOR CHILDREN WITH CF IN THE UK SURPASSES 50 FOR THE FIRST TIME
TRIKAFTA MAY BE SAFE AND EFFECTIVE FOR LIVER TRANSPLANT PATIENTS
P. AERUGINOSA BACTERIUM ADAPTS OVER TIME TO BECOME MORE RESISTANT
FDA AUTHORIZES FIRST ORAL ANTIVIRAL FOR TREATMENT OF COVID-19
OMICRON IS NOW THE DOMINANT CORONAVIRUS STRAIN IN THE UNITED STATES
MODERNA SAYS COVID BOOSTER APPEARS TO PROTECT AGAINST OMICRON
NOVEMBER, 2021
PHAGE THERAPY CLINICAL TRIAL RECRUITING PARTICIPANTS
LUNGFIT GO FOUND TO BE SAFE AND WELL-TOLERATED IN INTERIM TRIAL DATA
BOEHRINGER ACQUIRES RIGHTS TO POTENTIAL CF INHALATION GENE THERAPY
FDA ADVISERS VOTE TO RECOMMEND COVID-19 VACCINES FOR CHILDREN 5 TO 11
HEALTH DISPARITY IN CF: PERSPECTIVES FROM A LIVED EXPERIENCE
DIFFERENCES IN BACTERIAL COMMUNITIES AND INFLAMMATION IN LOWER AIRWAYS ARE EVIDENT BY AGE TWO
ARMATA PHARMACEUTICALS RECEIVES $3M FOR DEVELOPMENT OF PHAGE THERAPY
INCREASE IN PATIENT ADHERENCE TO THERAPY WITH GUIDED PLATFORM
CDC APPROVES PFIZER-BIONTECH COVID-19 VACCINE FOR YOUNGER CHILDREN
VACCINATION PROVIDES STRONGER, MORE RELIABLE PROTECTION AGAINST CORONAVIRUS THAN PAST INFECTION
ACERAGEN ACQUIRES POTENTIAL ORAL ANTIBIOTIC FOR CF PULMONARY FLARES
TRIKAFTA MAY BENEFIT SOME LUNG TRANSPLANT RECIPIENTS
GENE THERAPY SP-101 SHOWS POTENTIAL IN ANIMAL STUDY
PFIZER’S ANTIVIRAL PILL EFFECTIVE AGAINST COVID-19
RESEARCHERS IDENTIFY GENE THAT DOUBLES RISK OF RESPIRATORY FAILURE FROM COVID-19
GETTING TELEHEALTH POLICY RIGHT: A NATIONAL SUMMIT: READ SUMMARY | WATCH RECORDING
ELEXACAFTOR ALSO WORKS AS CFTR POTENTIATOR
BRONCHITOL–PULMOZYME COMBINATION EFFECTIVE IN CLEARING KIDS’ LUNGS
KIDS NASAL SWAB TESTS CONDUCTED BY PARENTS YIELD ACCURATE RESULTS
VIATRIS AND BIOCON BIOLOGICS ANNOUNCE LAUNCH OF INTERCHANGEABLE SEMGLEE®
COVID-19 CASES IN US ARE UP NEARLY 27% IN LAST THREE WEEKS, CDC SAYS
ELX-02 LOWERS SWEAT CHLORIDE IN PATIENTS WITH G542X MUTATION
P. AERUGINOSA METABOLITES MAY ENABLE BETTER THERAPEUTIC MANAGEMENT
HYPERTONIC SALINE FOUND TO BE EFFECTIVE AND SAFE FOR YOUNG CHILDREN WITH CF
OCTOBER, 2021
TRIKAFTA NOW COVERED IN 2 MORE CANADIAN PROVINCES
ANTIBIOTIC-RESISTANT BACTERIA IN FISH TREATED BY ADDING PHAGE THERAPY
ULTRASOUNDS MAY HELP DIAGNOSE PANCREATIC INSUFFICIENCY IN CHILDREN WITH CF
TWO STUDIES PROVIDE EVIDENCE THAT MASKS PROTECT CHILDREN FROM CORONAVIRUS – Study 1 – Study 2
COVID-19 VACCINES DO NOT INCREASE RISK OF MISCARRIAGE OR BIRTH DEFECTS
NIH DIRECTOR DR. FRANCIS COLLINS STEPPING DOWN
CF PATIENTS WITH COVID-19 AT HIGHER RISK OF POOR OUTCOMES
PHASE 1 STUDY OF KB407 TO BE LAUNCHED IN AUSTRALIA
CDC RELEASES GUIDANCE FOR UPCOMING HOLIDAY SEASON
FDA ISSUES BEST PRACTICES FOR COMMUNICATING CYBERSECURITY VULNERABILITIES TO PATIENTS
CDC RECOMMENDS COVID BOOSTER SHOT FOR ALL ADULTS
PFIZER AND BIONTECH SAY THEIR COVID-19 VACCINE IS 100% EFFECTIVE IN ADOLESCENTS AGED 12 TO 15 YEARS
OVERUSE OF ANTIBIOTICS DURING PANDEMIC FUELING DRUG-RESISTANT INFECTIONS
NEW ATS DOCUSERIES ON RESPIRATORY HEALTH
7 MILLION UNINSURED PEOPLE ARE ELIGIBLE FOR MEDICAID OR CHIP
INHALATION POWDER FOR MUCUS CLEARANCE AVAILABLE FOR THOSE WHO PASS THE BRONCHITOL TOLERANCE TEST
PHASE 1/2 TRIAL OF AEROSOL GENE THERAPY FOR CF MAY START SOON
GUT MICROBIOME SLOW TO DEVELOP IN CF INFANTS
EPICORE LAUNCHES WEARABLE PATCH TO CONDUCT SWEAT COLLECTION TESTS
PFIZER, BIONTECH ASK FDA TO AUTHORIZE CORONAVIRUS VACCINE FOR CHILDREN 5 TO 11 YEARS OLD
MERCK APPLIES FOR FDA EMERGENCY AUTHORIZATION FOR ANTIVIRAL PILL TO TREAT COVID-19
MOST MAC LUNG INFECTIONS LIKELY NOT PASSED FROM PATIENT TO PATIENT
LIVER DISEASE IN CF APPEARS LINKED TO PROBLEMS IN CFTR PROTEIN
ANIMAL CELL CULTURE-DEVELOPED FLU VACCINE EFFECTIVE IN CHILDREN
FDA PANEL BACKS BOOSTER DOSE FOR ALL J&J COVID-19 VACCINE RECIPIENTS
ANXIETY DUE TO COVID-19 LOWER IN CHILDREN WITH CF THAN THEIR PEERS
FDA PANEL RECOMMENDS MODERNA CORONAVIRUS BOOSTER FOR PEOPLE 65 YEARS AND OLDER, ADULTS AT HIGH RISK
SEPTEMBER, 2021
MS1819 PLUS PERT IMPROVED FAT ABSORPTION IN SEVERE EPI
CONTRIBUTE YOUR PERSONAL EXPERIENCES WITH TRIKAFTA TO CF RESEARCH
HEALTH DISPARITY IN CF: PERSPECTIVES FROM A LIVED EXPERIENCE
CENTERS FOR MEDICARE AND MEDICAID SERVICES ISSUE NEW CODE FOR ENCALA
PFIZER-BIONTECH’S COVID VACCINE RECEIVES FULL FDA APPROVAL
MONOCLONAL ANTIBODY TREATMENT HIGHLY EFFECTIVE AGAINST MILD TO MODERATE COVID-19
WORLD HEALTH ORGANZIATION CALLS FOR TWO-MONTH VACCINE BOOSTER MORATORIUM
LUNG CLEARANCE INDEX USEFUL IN ASSESSING LUNG FUNCTION
KALYDECO APPROVED IN CANADA TO TREAT INFANTS 4 MONTHS AND OLDER
FDA UNDER GROWING PRESSURE TO AUTHORIZE COVID-19 VACCINES FOR CHILDREN YOUNGER THAN 12
EXPERTS WORRY CHILDREN OF COLOR FACE GREATEST RISK AS COVID-19 INFECTS MORE CHILDREN IN US
CHOOSING AN AIR PURIFIER TO ADDRESS COVID AND WILDFIRE SMOKE
POLYPHOR AND ENBIOTIX TO MERGE, PLAN TRIALS IN 2 LUNG INFECTION THERAPIES
MINORITIES WITH CF MORE LIKELY TO EXPERIENCE LOWER LUNG FUNCTION THAN CAUCASIAN PATIENTS
PEDIATRIC HOSPITALIZATIONS DUE TO COVID-19 SPIKED DURING SUMMER MONTHS AMID DELTA VARIANT SPREAD
WHO MONITORING NEW CORONAVIRUS “VARIANT OF INTEREST.”
NORTH CAROLINA CO-PAY ACCUMULATOR BAN PASSES AND AWAITS GOVERNOR’S SIGNATURE
HHS PROPOSES TO WITHDRAW DRUG PRICING RULE
MORE AMERICANS HAD COVID-19 AT THE END OF 2020 THAN PREVIOUSLY ESTIMATED
ELX-02, POTENTIAL CF NONSENSE MUTATION THERAPY, ON FDA FAST TRACK
SFPQ PROTEIN HELPS TO RESTORE CFTR IN CELLS WITH COMMON MUTATION
STUDY SHOWS VALUE OF BIOFILM COMPONENT IN P. AERUGINOSARESISTANCE
FDA SAYS IT HOPES TO MOVE QUICKLY ON AUTHORIZING COVID-19 VACCINES FOR YOUNGER CHILDREN
THE FIGHT FOR A LIFE-CHANGING DRUG: GETTING TRIKAFTA APPROVED IN ALBERTA
PANDEMIC PLACES SOCIOECONOMIC HARDSHIPS ON CF PATIENTS
PUBLIC REIMBURSEMENT OF TRIKAFTA ONE STEP CLOSER IN CANADA
AIRPHYSIO LUNG CLEARANCE DEVICE NOW SOLD ONLINE FOR U.S. PATIENTS
JOHNSON & JOHNSON’S COVID-19 VACCINE IS MORE EFFECTIVE WHEN GIVEN AS A TWO-DOSE REGIMEN
ONE IN THREE PEOPLE WHO SURVIVED COVID-19 REPORT SUFFERING FROM LONG COVID
EMILY’S ENTOURAGE HOSTED FDA LISTENING SESSION FOR THE FINAL 10% OF PEOPLE WITH CYSTIC FIBROSIS
FTC ISSUES STATEMENT CONFIRMING CONNECTED DEVICES MUST COMPLY WITH DATA BREACH RULE
AUGUST, 2021
SECRETORY CELLS DOMINATE AIRWAY CFTR EXPRESSION AND FUNCTION IN HUMAN AIRWAY SUPERFICIAL EPITHELIA
SEMGLEE APPROVED AS FIRST INTERCHANGEABLE BIOSIMILAR INSULIN PRODUCT
INDIVIDUALS WITH CYSTIC FIBROSIS DO NOT APPEAR TO HAVE HIGHER RISK FOR SARS-COV-2 INFECTION
NUTRITIONAL STATUS OF CHILDREN WITH CF LINKED TO TEENAGE-ONSET DIABETES
SANOFI TO ACQURE TRANSLATE BIO
CDC SUGGESTS VACCINATED INDIVIDUALS INFECTED WITH DELTA CORONAVIRUS VARIANT CARRY HIGH VIRAL LOADS
IT IS TIME TO LET GO OF THE QALY”S LEGACY OF DISCRIMINATION
LOW BONE DENSITY IN CF ADULTS MAY BE TIED TO INFLAMMATION MARKER
CFTR PROTEIN DYNAMIC, CHANGING SHAPES IN WAYS AFFECTING DISEASE
CHRONIC SINUS INFLAMMATION MAY ALTER BRAIN ACTIVITY
BIONTECH SAYS BOOSTER SHOT A BETTER STRATEGY THAN TAILORING VACCINE TO NEW VARIANT
US TOPS 100,000 DAILY COVID-19 CASES FOR FIRST TIME SINCE WINTER
STUDY SHOWS J&J COVID-19 VACCINE 96.2% EFFECTIVE AGAINST SEVERE ILLNESS AND DEATH
HHS PROPOSES TO WITHDRAW DRUG PRICING RULE
INSURERS OPPOSE HHS PROPOSAL TO EXTEND ACA ANNUAL ENROLLMENT PERIOD
COLLEGE STUDENT WITH CF APPOINTED TO NEW RARE DISEASE ADVISORY COUNCIL IN OHIO
ATS/AMERICAN LUNG ASSOC. JOINT STATEMENT OPPOSING PHILLIP MORRIS INT’L BID TO AQUIRE VECTURA
PATIENT GROUPS AMENDMENTS TO CALIFORNIA AB 1130
PRIME EDITING, ADVANCE ON CRISPR, SHOWS POTENTIAL ON CFTR MUTATIONS
NEW METHOD TO PRODUCE HIGH-YIELD, HIGH-PURITY RNA MAY AID CF TREATMENT
LUNG TRANSPLANT BIOREPOSITORY, REGISTRY TARGETS PATIENT OUTCOMES
BOOSTER DOSE OF COVID VACCINE NOW RECOMMENDED FOR THE IMMUNO-COMPROMISED
CALIFORNIA SENATE BILL 247 TO BE HEARD IN ASSEMBLY APPROPRIATIONS COMMITTEE AUGUST 19
LETTER IN OPPOSITION TO PMI ACQUISITION OF VECTURA
INSURERS OPPOSE HHS PROPOSAL TO EXTEND ACA ANNUAL ENROLLMENT PERIOD
BABIES AND TODDLERS SPREAD VIRUS IN HOMES MORE EASILY THAN TEENS, STUDY FINDS
RACIAL, SOCIAL DISPARITIES INFLUENCE ASTHMA-RELATED HOSPITAL READMISSIONS
JULY, 2021
THE WHO SAYS FULLY VACCINATED PEOPLE SHOULD CONTINUE TO WEAR FACE MASKS IN PUBLIC SETTINGS
LOW LEVELS OF VIP HORMONE MAY CONTRIBUTE TO EARLY CF-RELATED DIABETES
SEVERE COVID-19 MORE LIKELY IN CF CARRIERS THAN PATIENTS
JOINT DISEASE LINKED TO P. AERUGINOSA INFECTION, FEMALE SEX
SOME MINORS SEEK TO GET COVID-19 VACCINE AGAINST PARENTS’ WISHES
STUDY SUGGESTS MODERNA COVID-19 VACCINE EFFECTIVE AGAINST DELTA VARIANT
DELTA VARIANT IS MAKING OFFICIALS RETHINK MASK GUIDELINES
WHO ESTIMATES YEARLY COVID-19 BOOSTERS MAY BE NEEDED FOR MOST VULNERABLE
SUPREME COURT REJECTS LATEST CHALLENGE TO AFFORDABLE CARE ACT
TENSIN 1 GENE VARIANTS MAY AFFECT NUTRITION IN CF PATIENTS
ARROWHEAD PAUSES ARO-ENAC STUDY AMID SAFETY CONCERNS
11% OF PEOPLE IN THE U.S. HAVE MISSED THEIR SECOND COVID-19 VACCINE DOSE
AIRWAY INFLAMMATION AFFECTS PH, RESPONSE TO CFTR THERAPIES
DATA FROM PHASE 2 TRIALS OF ELX-02 EXPECTED THIS YEAR
UNDERVACCINATED CLUSTERS MAY BECOME BREEDING GROUNDS FOR MORE FATAL CORONAVIRUS VARIANTS
PFIZER-BIONTECH TO SEEK FDA AUTHORIZATION FOR THIRD DOSE OF COVID-19 VACCINE
FDA CLEARS TACROLIMUS TO PREVENT LUNG TRANSPLANT REJECTION
HORMONE FLUCTUATIONS TIED TO CHANGES IN LUNG FUNCTION IN WOMEN WITH CYSTIC FIBROSIS
STUDY DESCRIBES NEW COMPOUND FOR NONSENSE MUTATIONS
FDA GRANTS PRIORITY REVIEW TO PFIZER-BIONTECH’S APPLICATION FOR FULL APPROVAL OF COVID-19 VACCINE
WILDFIRE SMOKE MAY INCREASE RISK OF COVID-19
JUNE, 2021
RACE, INCOME LIMIT CF LUNG TRANSPLANT ACCESS IN US MORE THAN CANADA
ELOXX ANNOUNCES FUNDING AWARD FROM CFF FOR DEVELOPMENT OF RIBOSOME MODULATING AGENTS (RMAs)
BENEFITS OF TRIPLE-COMBO TRIKAFTA FOR CF MOSTLY DUE TO ELEXACAFTOR
NEW CELL RESEARCH MODEL SHOWS PROMISE AGAINST P. AERUGINOSA
DR. FAUCI URGES VACCINATION AGAINST COVID-19 VARIANT SPREADING TO US FROM INDIA
UNITEDHEALTHCARE DELAYS PLANS TO DENY SOME EMERGENCY VISITS AMID OUTCRY
ANTIBODY-LADEN NASAL SPRAY COULD PROVIDE COVID PROTECTION
PHILIPS RECALLS MILLIONS OF VENTILATORS, SLEEP APNEA DEVICES OVER POTENTIAL HEALTH RISKS
RNA-BASED THERAPIES SHOW PROMISE IN EARLY STUDIES
MOLECULES IN PATIENTS’ BREATH MAY INDICATE P. AERUGINOSA INFECTION
STUDY SHOWS THAT COVID-19 BOOSTER SHOT MAY HELP PROTECT SOME TRANSPLANT PATIENTS
CASES OF COVID-19 DELTA VARIANT ARE RISING IN THE US
TRIAL RESULTS SHOW NOVAVAX COVID-19 VACCINE CANDIDATE 90.4% EFFECTIVE
VACCINATION RATES AMONG LATINX AND AFRICAN AMERICAN COMMUNITIES LAG BEHIND
MODERNA APPLIES FOR FDA AUTHORIZATION FOR USE OF ITS COVID-19 VACCINE IN ADOLESCENTS
U.S. TO BUY 500M DOSES OF PFIZER-BIONTECH VACCINE FOR OTHER COUNTRIES
HEALTH CANADA APPROVES TRIKAFTA FOR CF PATIENTS AGES 12 AND UP
NEW STRATEGY CORRECTS CF SPLICING DEFECTS IN LAB MODELS
YOUNGER ADULTS’ COVID-19 VACCINATION RATES SLOWER THAN OLDER ADULTS
MANY LOW-INCOME IMMIGRANTS RESORT TO UNPROVEN COVID-19 TREATMENTS
SUPREME COURT REJECTS LATEST CHALLENGE TO AFFORDABLE CARE ACT
DELTA COVID-19 VARIANT SPREADING IN UNVACCINATED US COUNTIES, ANALYSIS FINDS
MAY, 2021
NEW CRISPR TECHNOLOGY OFFERS CONTROL OF EPIGENETIC INHERITANCE
SOCIAL DISTANCING INSIDE CAN PROVIDE A FALSE SENSE OF SECURITY
KB407 GENE THERAPY FOUND SAFE IN ANIMALS, IN-HUMAN TRIAL EXPECTED LATER THIS YEAR
CDC SAYS FULLY VACCINATED AMERICANS CAN NOW GO OUTSIDE WITHOUT A MASK
CPAP THERAPY MAY AFFECT BMI IN ADULTS WITH OSA, STUDY INDICATES
MANY PEOPLE STILL PREFER CONVENIENCE OF JOHNSON AND JOHNSON ONE-DOSE COVID-19 VACCINE
FDA PROMISES TO ISSUE NEW RULES WITHIN A YEAR BANNING MENTHOL IN TOBACCO PRODUCTS
REACHING ‘HERD IMMUNITY’ IS UNLIKELY IN THE U.S
CHILDREN ACCOUNT FOR 22.4% OF NEW #COVID19 CASES IN THE US
WORLD ORPHAN DRUG CONGRESS: RARE DISEASE TRIALS AND PATIENT REGISTRIES
FDA TO AUTHORIZE PFIZER-BIONTECH COVID-19 VACCINE FOR CHILDREN AGES 12 – 15
PDE4 INHIBITORS MAY HELP TREAT CF, DRY MOUTH
EU OPENS KAFTRIO TO ALL CF PATIENTS 12 AND UP WITH F508DEL MUTATION
ELOXX ADDS KALYDECO TO ONGOING PHASE 2 TRIAL OF ELX-02
OP-ED: ANTIBIOTIC RESISTANCE, CHRONIC DISEASE AND COVID-19 – A TRIPLE THREAT
CDC UPDATES GUIDELINES ON CORONAVIRUS, EMPHASIZING AIRBORNE TRANSMISSION
TOBRAMYCIN GIVEN IN NANOPARTICLES SHOWS POTENTIAL TO TREAT P. AERUGINOSA
MS1819 PLUS PERT IMPROVES DIGESTION IN PEOPLE WITH SEVERE EPI
SPLISENSE RAISES $28.5 MILLION TO ADVANCE RESTORATIVE CF THERAPY
SURVEY FINDS THAT MANY UNVACCINATED LATINX ADULTS IN THE US WANT COVID-19 SHOT
CDC SAYS FULLY VACCINATED CAN GO WITHOUT MASKS OR PHYSICAL DISTANCING IN MOST CIRCUMSTANCES
SPIROMETRY MEASUREMENTS TAKEN AT HOME DON’T MATCH WITH THOSE OBTAINED IN CLINIC
EU, UK CONSIDER EXPANDING KAFTRIO TO CHILDREN AGES 6 AND OLDER
TWO STUDIES INDICATE COVID-19 MITIGATION MEASURES CAN HELP SCHOOLS STAY OPEN AND KEEP STUDENTS SAFE
US CHILDREN WITH CF HAVE BETTER LUNG FUNCTION THAN UK CHILDREN
HEALTH DISPARITY OBVIOUS IN AVAILABLE TREATMENTS FOR SICKLE CELL COMMUNITY
APRIL, 2021
SWEAT-MEASURING STICKER MAY AID CF DIAGNOSIS IN CHILDREN
LEAVING MIDDLE SEATS ON AIRPLANES VACANT MAY REDUCE RISK OF CORONAVIRUS EXPOSURE
RISK OF BRAIN BLOOD CLOTS IS HIGHER FROM COVID-19 INFECTION THAN FROM COVID-19 VACCINES
EXPERTS CONCERNED ABOUT IMPACT OF J&J CORONAVIRUS VACCINE PAUSE
FREE ONLINE CLASSES FOR THE CF COMMUNITY AT STROLO UNIVERSITY
OPTION 2 TRIAL TESTING MS1819 FOR EPI POSTS ‘MIXED’ TOPLINE RESULTS
RESPINOVA’S PULSEHALER DEVICE RECEIVES FDA APPROVAL
PHASE 2 TRIAL ADVANCING: BX004, PHAGE THERAPY FOR BACTERIAL INFECTIONS
RACIAL BIAS IN PULSE OXIMETRY MEASUREMENTS
APRIL 24TH IS TAKE BACK DAY – AN IMPORTANT REMINDER TO SAFELY DISPOSE OF UNUSED MEDICATION
CDC: HALF OF ALL US ADULTS HAVE RECEIVED AT LEAST ONE COVID-19 VACCINE DOSE
MARCH, 2021
FEBRUARY, 2021
OP-ED: SB 5020 INCLUDES GROUP KNOWN FOR DISCRIMINATORY PRACTICES
ASTRAZENECA VACCINE APPEARS TO SUBSTANTIALLY REDUCE TRANSMISSION OF THE CORONAVIRUS
FDA TO REVIEW TRIKAFTA FOR PATIENTS AS YOUNG AS SIX YEARS
KINNEAR PHARMACEUTICALS TO RECEIVE UP TO $3M TO FOR DEVELOPMENT OF ANTI-INFECTIVE FROM CF FOUNDATION
TRANSMISSION AND ANTIBIOTIC RESISTANCE OF ACHROMOBACHTER BACTERIA IN CYSTIC FIBROSIS
JANUARY, 2021
MS THERAPY BOOSTS TOBRAMYCIN’S EFFECTIVENESS AGAINST P. AERUGINOSA
AzurRx STARTS DOSING FIRST CF PATIENTS IN STUDY OF LIPASE ENZYME MS1819
MINORITIES IN US OFTEN INELIGIBLE FOR CFTR MODULATORS DUE TO POORLY STUDIED MUTATIONS